Despite the progress achieved in the eradication of H. pylori, the emergence of resistant strains of microorganism requires the search for new medications and treatment regimens. Methods. The study involved 160 children aged 8-18 years with disorders of the upper gastrointestinal tract associated with Helicobacter. Mucosal biopsies were used for detection of H. Pylori, CagA antigen and antibodies to CagA antigen were tested in stool before the treatment and 4-6 weeks after the treatment (eradication control). Children were divided into eight groups according to the schemes of Helicobacter therapy. The processing of the results was performed using data analysis package Microsoft Office Excel (2003). The difference of indices between the groups was determined using Student's t criteria and considered to be significant at p <0.05. Results. It was figured out that in children who took proton pump inhibitors, clarithromycin and nifuratel during 7 and 10 days in anti-Helicobacter therapy was the fastest regression of the main clinical manifestations of the disease was observed (p<0.05). The highest effect of eradication was achieved in patients taking proton pump inhibitor, clarithromycin and nifuratel within 10 days (90 %, decrease of relative risk of recurrence is 0.44 (CI: 0.17-5.45), and the number of patients who should receive treatment to achieve one positive . Conclusions.1. Different efficiency of Helicobacter therapy in children with Helicobacter-associated pathologies of the upper gastrointestinal tract was determined. 2. Eradication of H. pylori was observed in 80% of children in third, sixth and seventh groups. The most effective scheme of anti-Helicobacter therapy in children was the use of proton pump inhibitor, clarithromycin and nifuratel within 10 days (90 % eradication